Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 102 increasing their positions, 75 reducing their positions, and 29 closing their positions.
338% more call options, than puts
Call options by funds: $89.5M | Put options by funds: $20.4M
114% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 29
81% more capital invested
Capital invested by funds: $3.05B → $5.5B (+$2.45B)
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
36% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 75
14% more funds holding
Funds holding: 236 → 268 (+32)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$123M |
| 2 |
PA
Perceptive Advisors
New York
|
+$88M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$52.9M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$41.6M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$33.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$114M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$84M |
| 3 |
Millennium Management
New York
|
-$30.8M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$30.7M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$27.6M |
ARRY Hedge Fund Activity: Q1 2019 in Review
268 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2019, worth a combined $5.5B — up 81% from $3.05B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new ARRY positions and 29 closed out — a net gain of 33 holders — while 102 added to existing stakes and 75 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was Redmile Group, cutting an estimated $114M.
- 268 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2019, up from 236 in Q4 2018.
- Funds reported $5.5B of Array Biopharma Inc stock for Q1 2019, up 81% quarter-over-quarter.
- 62 funds opened new Array Biopharma Inc positions in Q1 2019 and 29 closed out, a net change of +33 holders.
- The largest Array Biopharma Inc buyer in Q1 2019 was T. Rowe Price Associates, an estimated $123M added.
- The largest Array Biopharma Inc seller in Q1 2019 was Redmile Group, an estimated $114M sold.
Based on aggregated 13F filings for Q1 2019.